NeoGenomics Inc. Common Stock vs Vanguard Total International Stock Index Fund ETF — how do they compare? NeoGenomics Inc. Common Stock trades at $16.85 (market cap $2.14B), while Vanguard Total International Stock Index Fund ETF trades at $83.12 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 311.1× NeoGenomics Inc. Common Stock's market cap, and Vanguard Total International Stock Index Fund ETF is more actively traded (4,659,186 versus 2,228,400). Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and Vanguard Total International Stock Index Fund ETF for 56 Days on average.
| NEO | VXUS | |
|---|---|---|
Market Cap | $2.14B | $665.70B |
Volume | 2,228,400 | 4,659,186 |
Sector | Health | Sector/Thematic |
52-Week High | $19.91 | $88.41 |
52-Week Low | $7.19 | $72.19 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $2.44B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VXUS trades at $84.54 with minimal daily movement (+0.12%). Technical indicators show bearish momentum with moving averages signaling sell pressure, while oscillators remain neutral. The ETF provides broad international stock exposure outside the U.S., offering diversification benefits. Recent institutional activity shows growing interest, with firms like QRG Capital increasing positions by 97.8% in Q2 2026 (SEC filing, September 2026).
VXUS offers cost-effective international diversification but faces currency and geopolitical risks. Current bearish technicals suggest near-term pressure, while long-term prospects depend on global market performance versus U.S. equities. The upcoming $0.16 dividend in September 2026 provides income, but foreign tax credit limitations in IRAs may reduce net returns for some investors (24/7 Wall Street, August 2026).
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →